Management of fracture risk in CKD—traditional and novel approaches
Open Access
- 22 October 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 16 (3) , 456-472
Abstract
The coexistence of osteoporosis and chronic kidney disease (CKD) is an evolving healthcare challenge in the face of increasingly aging populations. Globally, accelerating fracture incidence causes disability, impaired quality of life and increased mortality. Consequently, several novel diagnostic and therapeutic tools have been introduced for treatment and prevention of fragility fractures. Despite an especially high fracture risk in CKD, these patients are commonly excluded from interventional trials and clinical guidelines. While management of fracture risk in CKD has been discussed in recent opinion-based reviews and consensus papers in the nephrology literature, many patients with CKD stages 3–5D and osteoporosis are still underdiagnosed and untreated. The current review addresses this potential treatment nihilism by discussing established and novel approaches to diagnosis and prevention of fracture risk in patients with CKD stages 3–5D. Skeletal disorders are common in CKD. A wide variety of underlying pathophysiological processes have been identified, including premature aging, chronic wasting, and disturbances in vitamin D and mineral metabolism, which may impact bone fragility beyond established osteoporosis. We discuss current and emerging concepts of CKD–mineral and bone disorders (CKD-MBD) and integrate management of osteoporosis in CKD with current recommendations for management of CKD-MBD. While many diagnostic and therapeutic approaches to osteoporosis can be applied to patients with CKD, some limitations and caveats need to be considered. Consequently, clinical trials are needed that specifically study fracture prevention strategies in patients with CKD stages 3–5D.Keywords
This publication has 180 references indexed in Scilit:
- Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium dietsKidney International, 2012
- The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2012
- A single-dose study of denosumab in patients with various degrees of renal impairmentJournal of Bone and Mineral Research, 2012
- Differences in Bone Quality in Low- and High-Turnover Renal OsteodystrophyJournal of the American Society of Nephrology, 2012
- The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to KnowThe Journal of Clinical Endocrinology & Metabolism, 2011
- The link between bone and coronary calcifications in CKD-5 patients on haemodialysisNephrology Dialysis Transplantation, 2010
- Analysis of hip geometry by clinical CT for the assessment of hip fracture risk in elderly Japanese womenBone, 2010
- Utility of serum tartrate‐resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunctionClinical Endocrinology, 2008
- The Effect of Raloxifene Treatment in Postmenopausal Women with CKDJournal of the American Society of Nephrology, 2008
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002